September 6, 2017 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer

Basel, 06 September 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche (SIX: RO,... Read more

September 5, 2017 Clinical Research/Diagn. Lab Top-10 PR/Corporate Product Launch

Agilent Receives 2017 Scientists' Choice Award for Best New Clinical Laboratory Product

Awarded to the Agilent IQFISH Panel for Lung Cancer SANTA CLARA, Calif., September 5, 2017 Agilent Technologies Inc. (NYSE: A) has received a 2017 Scientists’ Choice Award for Best New Clinical Laboratory Product: the IQFISH Panel for Lung Cancer. The IQFISH panel for lung cancer makes it easier for pathology labs to integrate fast, high-quality... Read more

September 5, 2017 Clinical Research/Diagn. Life Science Tools Product Launch

New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings

New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings Analysis shows that high quality BRAHMS PCT (procalcitonin) assays are reliable tools to assist in the safe management of patients with suspected bacterial infection and sepsis HENNIGSDORF, Germany, Sept. 5, 2017 /PRNewswire/ — A new study, recently... Read more

September 1, 2017 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies... Read more

August 31, 2017 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Seegene accelerates ‘Project 100’ by securing 30 co-development partners

2017.08.31 Seoul, Korea, 2017/08/31 – Seegene, the world’s leading developer of multiplex molecular technologies and assays, announced that it has recently signed collaborative contracts with 30 general hospitals and reference laboratories across 15 nations for the co-development of ‘Project 100’ products. Contracting parties are mostly the largest commercial labs in the country, university hospitals, and... Read more

August 31, 2017 Clinical Research/Diagn. PR/Corporate Product Launch

Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress

Basel, 31 August 2017 Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO... Read more

August 28, 2017 Chromatography Clinical Research/Diagn. Lab Top-10 Product Launch

Phenomenex Publishes Second Edition of Comprehensive Clinical Application Notebook

Torrance, Calif. (August 28, 2017) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the publication of a new clinical application guide. This 136-page digital notebook is the second edition of the guide and presents 36 updated or entirely new applications developed by PhenoLogix™, Phenomenex’s... Read more

August 15, 2017 Clinical Research/Diagn. Informatics & Software M&A, Partnerships

Seven Bridges Selected To Build Groundbreaking Data Analysis Platform To Fight Pediatric Disease

August 15, 2017 New data resource center will be created with the NIH and Children’s Hospital of Philadelphia to enable pediatric research across both cancer and structural birth defects datasets for the first time BOSTON, Mass., and PHILADELPHIA, Penn., August 15, 2017 –  Seven Bridges, the biomedical data analysis company, today announced that it has been selected... Read more

August 10, 2017 Clinical Research/Diagn. Lab Top-10

Beckman Coulter Diagnostics Announces Enhancements to the Access 2 Immunoassay System

Built upon a 20 year legacy of reliable and efficient performance, the Access 2 delivers new features that advance end-user experience and productivity. BREA, Calif., Aug. 10, 2017 /PRNewswire/ — Beckman Coulter Diagnostics is pleased to announce worldwide availability of the Access 2 immunoassay system with enhanced features. Built upon a 20-year legacy of reliable and efficient performance, the Access... Read more